fda 503a bulks list bpc-157 category 2 HHS Secretary RFK Jr. just dropped major news: the is removing 12 peptides from its restrictive — reversing the 2023 crackdown that shut down compounding pharmacies and fueled BPC-157 Legal Status: FDA Regulations

Its primary mechanism involves stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation) by mimicking the fat-reducing effects of human growth hormone

Strictly designated for in vitro and laboratory research use only

AstraZeneca said the antibody-drug conjugate, acquired through its 2023 licensing deal with KYM Biosciences, has blockbuster potential with projected peak sales of $3 billion to $5 billion

BPC 157 and Standard Angiogenic Growth Factors Key Findings: BPC-157, when compared to standard peptidergic angiogenic growth factors (EGF, FGF, VEGF), has been effective in all models of acute/chronic injury of the gastrointestinal tract, whether administered intraperitoneally, per-orally, or locally